MEDI5752

Phase 2Small molecule

AstraZeneca

MEDI5752 is one of 151 small molecule programs targeting Advanced or Metastatic NSCLC. It is currently in Phase 2.

Indications

Total Trials

Active Trials

150

Competitors

Pipeline

Status by Indication[3][1]

Indication

Advanced or Metastatic NSCLCActive, not recruiting

Selected Advanced Solid TumorsActive, not recruiting

Solid TumorsNot yet recruiting

CancerActive, not recruiting

Renal Cell CarcinomaActive, not recruiting

Advanced or Metastatic NSCLCPhase 1

Active, not recruiting

Selected Advanced Solid TumorsPhase 1

Active, not recruiting

Solid TumorsPhase 2

Not yet recruiting

CancerPhase 1

Active, not recruiting

Renal Cell CarcinomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

137 competitors in Solid Tumors

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 3

6 2

Lynparza

AstraZeneca

Phase 3

4 3

Lenvima

Eisai

Phase 3

3 4

Taxol

Teva

Phase 2

15 5

Gemzar

Johnson & Johnson

Phase 2

12 6

Opdivo

Bristol-Myers Squibb

Phase 2

10 7

Beyfortus

BeiGene

Phase 2

5 8

Fludara

Sanofi

Phase 2

3 9

Camptosar

Pfizer

Phase 2

3 10

Taxotere

AAvyxa

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Active, not recruiting

Advanced or Metastatic NSCLC

NCT04612751

Q4 2027

Phase 1Active, not recruiting

Selected Advanced Solid Tumors

NCT03530397

Q3 2028

Phase 2Not yet recruiting

Solid Tumors

NCT05888857

Clinical

Trials by Indication[1]

Renal Cell Carcinoma1 trial

A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 1·NCT04522323·67 enrolled

Solid Tumors1 trial

MEDI5752 in Patients With Mature Tertiary Lymphoid Structures Solid Tumors.

Not yet recruiting·IInstitut Bergonié·Phase 2·NCT05888857·102 enrolled

Cancer1 trial

A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 1·NCT03819465·175 enrolled

Patients With Advanced Solid Tumors1 trial

MEDI5752 in Japanese Patients With Advanced Solid Tumors.

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT05685472·6 enrolled

Selected Advanced Solid Tumors1 trial

A Phase 1, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability Pharmacokinetics Immunogenicity, and Antitumor Activity of MEDI5752 in Subjects With Advanced Solid Tumors.

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 1·NCT03530397·400 enrolled

1 more indication

Advanced or Metastatic NSCLC1 trial

A Phase 1b, Multicenter, 2-Part, Open-Label Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Immunotherapy With or Without Carboplatin in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (Tropion-Lung04)

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 1·NCT04612751·155 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for MEDI5752. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MEDI5752 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MEDI5752. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AstraZeneca

MEDI5752

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q4 2027

Q3 2028

Trials by Indication[1]

Renal Cell Carcinoma1 trial

Solid Tumors1 trial

Cancer1 trial

Patients With Advanced Solid Tumors1 trial

Selected Advanced Solid Tumors1 trial

Advanced or Metastatic NSCLC1 trial

References

Drug Info

Quick Facts

Related News